Clinical trials

Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour […]

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that with a median of 13-19 months of follow-up, talquetamab continues to […]

Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility.  The study aimed […]

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme.   The data were from preclinical models of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction.    Vicore Pharma states that results from the trial are expected in Q4, 2023.  The study   Vicore is conducting a randomised, double-blind, placebo-controlled, cross-over […]

Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel […]

Eli Lilly’s tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.   The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimands. Those taking tirzepatide lost up to 15.7% (34.4lb or 15.6kg) of body weight for the efficacy estimand.   […]

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?” With Covid-19 taking so […]

UK-based pharmaceutical company AstraZeneca has seen its market value overtake its US rival Pfizer’s, just days before the company releases its quarterly earnings.   AstraZeneca is now topping the London Stock Exchange with a market value of £189 billion – a rise of 19.60% since the same time last year.   On the New York Stock Exchange, […]

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study that provides the first clinical proof-of-concept for effectively drugging […]

By Lucy Radley, Senior Vice President, Head of European Regulatory Development at ProPharma Group.  Clinical trials are, undoubtedly, an essential part of the drug development process, providing us with valuable information about the safety and efficacy of new treatments and therapies. However, despite their deep importance to the wellbeing of patients, persistent inequalities continue to […]

This paid-for advertorial by BC Platforms appeared in DDW Volume 24 – Issue 2, Spring 2023 BC Platforms’ Global Data Partner Network provides patient-level, longitudinal, and geographically diverse real-world data and real-world evidence for use as external control arms in randomised human clinical trials, which can accelerate medicinal product regulatory filings and market access. In […]

CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options.  The trial   The trial is led […]

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will also invest in oncology-specific innovation […]